Navegando por Palavras-chave "Sodium Nitroprusside"

Agora exibindo 1 - 2 de 2
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Avaliação da eficácia de doses repetidas de nitroprussiato de sódio no tratamento da esquizofrenia resistente: um estudo duplo-cego, randomizado, controlado por placebo
    (Universidade Federal de São Paulo (UNIFESP), 2020-08-21) Adelino, Marcelo Pinheiro Machado [UNIFESP]; Lacerda, Acioly Luiz Tavares De [UNIFESP]; Universidade Federal de São Paulo
    In present study, we evaluated the efficacy of repeated-dose sodium nitroprusside (SNP) in treatment-resistant schizophrenia. Methods: This was a double-blind, randomized, placebo-controlled trial. Twenty DSM-IV schizophrenia subjects, aged 18-60 years, with a history of nonresponse to ≥2 trials of antipsychotics used in adequate dose and duration (≥6 weeks) were enrolled. Subjects received SNP or placebo 4-hour infusions at 0.5 μg/kg/min. A total of 4 infusions and 4 follow-up evaluations, with an interval of 2 weeks, were performed. Severity of symptoms was assessed by using Positive and Negative Syndrome Scale (PANSS), Brief Psychiatric Rating Scale (BPRS-18) and Clinical Global Impression (CGI) scales. Results: SNP and placebo groups did not differ at baseline or in change from baseline for PANSS-total F3.597, 64.748=0.398; p=0.790), PANSS-positive (F2.898, 52.167=0.509; p=0.672), PANSS general (F3.302, 59.431=0.243; p=0.983), BPRS (F4.312, 77.615=0.143; p=0.946), or CGI (F3.841, 69.131=1.096; p=0.364) scores. SNP was well tolerated and showed a good safety profile. Conclusion: Although preliminary, the present findings suggest that SNP is not efficacious in TRS, reinforcing previous studies that have not demonstrated symptom improvement in chronic schizophrenia subjects. At this time, it is conceivable to speculate that efficacy of SNP might be restricted to early stages of disease.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Avaliação da eficácia do nitroprussiato de sódio no tratamento de sintomas negativos da esquizofrenia resistente: um estudo duplo-cego, randomizado, controlado por placebo
    (Universidade Federal de São Paulo (UNIFESP), 2020-08-21) Nunes, Marcel Vella [UNIFESP]; Lacerda, Acioly Luiz Tavares De [UNIFESP]; Universidade Federal de São Paulo
    To evaluate the efficacy, tolerability and safety of the administration of repeated doses of sodium nitroprusside (SNP) for the treatment of negative symptoms in patients with treatment-resistant schizophrenia (TRS). Methods: This is a doubleblind, randomized, placebo-controlled clinical trial. Twenty participants with a diagnosis of schizophrenia according to the DSM-IV-TR criteria were included, with a documented history of non-response to ≥2 antipsychotic treatments, with adequate dose and duration (≥6 weeks). Participants were randomized and received 4-hour sodium nitroprusside or placebo infusions at 0.5 μg / kg / min, which were performed under strict monitoring. Four infusions were performed, with an interval of 2 weeks between infusions for each participant and 4 follow-up evaluations. The primary outcome was the negative subscale of the Positive and Negative Syndrome Scale (PANSS). Secondary measures included changes in the total PANSS score, the Brief Psychiatric Rating Scale (BPRS), the Global Clinical Impression Scale (CGI) and the Udvalg for Kliniske Undersøgelser (UKU), used to assess adverse events. Results: There were no differences between the SNP and placebo groups for changes in total PANSS score (F = 0.525; p = 0.841), or negative PANSS subscale (F = 1.053; p = 0.483). The groups did not differ regarding the change in the BPRS scores (F = 0.615; p = 0.734) or CGI-S (F = 1.11; p = 0.416). The changes in blood pressure and heart rate were not clinically significant, there were no serious adverse events and it was not necessary to suspend the infusion with any participant, that is, SNP had a good tolerability and safety profile. Conclusion: Present findings of this study suggest that the SNP is not efficacious for the treatment of negative symptoms in patients with TRS, therefore it is conceivable to consider that the effectiveness of the SNP may be restricted to the early stages of the disease and to a younger population. Future studies examining larger samples and including patients at different stages of the disease, as well as at different ages, can be particularly clarifying.